Search | Clinical Trials Finder

Conditions: Glioma
Interventions: AG881; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 6 more

Conditions: Acute Myeloid Leukaemia
Interventions: S 64315 (also referred as MIK665) and venetoclax; Combination Product
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: New Haven, Connecticut • Houston, Texas

Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions: S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 20
States / cities: Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Interventions: Ivosidenib, Durvalumab (for the first 8, 21-day, cycles), Gemcitabine (for the first 8, 21-day, cycles), Cisplatin (for the first 8, 21-day, cycles), Durvalumab (starting from cycle 9), Ivosidenib Recommended Combination Dose (RCD); Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Los Alamitos, California • Los Angeles, California • Chicago, Illinois + 5 more

Conditions: Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Interventions: UCART19; Biological
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: Up to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Los Angeles, California • Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Primary Sjögren's Syndrome
Interventions: S95011 concentrate for solution for infusion, Placebo concentrate for solution for infusion; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Lakewood, Colorado • Duncansville, Pennsylvania

Conditions: Advanced Lymphoid Leukemia
Interventions: UCART19 follow-up; Biological
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 7
States / cities: Los Angeles, California • Denver, Colorado • Tampa, Florida + 4 more

Conditions: MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Interventions: S095029, pembrolizumab 200 mg (KEYTRUDA ®); Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Ocala, Florida • Noblesville, Indiana • Houston, Texas

Conditions: Glioma
Interventions: AG-120, AG881; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Osteoarthritis
Interventions: GLPG1972, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 932 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 38 more

Conditions: Uveitis
Interventions: Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 52
States / cities: Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 49 more

Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury
Interventions: AG-120, AG-221, cytarabine, daunorubicin, idarubicin, mitoxantrone, etoposide; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Calaspargase pegol (S95015); Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 22 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more

Conditions: Epileptic Encephalopathy
Interventions: S230815- Starting dose A, S230815- Dose B, S230815- Dose C, S230815- Dose D; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 2 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Orange, California • Boston, Massachusetts • Rochester, New York + 2 more

Conditions: IDH1-mutant Glioma, IDH2-mutant Glioma
Interventions: Vorasidenib, Temozolomide (TMZ); Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 12 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Interventions: Ivosidenib 500mg, Placebo; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 19 more

Conditions: Uveitis
Interventions: Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab; Drug
Lead sponsor: XOMA (US) LLC; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 51
States / cities: Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 48 more

Conditions: MTAP-deleted Solid Tumors
Interventions: S095035, TNG462; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Lake Mary, Florida • Indianapolis, Indiana • Maumee, Ohio + 2 more

Conditions: Hepatic Impairment
Interventions: Vorasidenib; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Refractory Metastatic Colorectal Cancer
Interventions: Trifluridine/Tipiracil, Bevacizumab; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Phoenix, Arizona • Duarte, California • South Pasadena, California + 9 more

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: UCART19; Biological
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 16 Years to 69 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas

Conditions: IDH1-Mutated Malignancies
Interventions: Ivosidenib Oral Tablet; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia • Columbus, Ohio • Houston, Texas

Conditions: Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: S64315 once a week, S64315 twice a week; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Houston, Texas

Conditions: Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Interventions: AG-120, Placebo; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 26
States / cities: Scottsdale, Arizona • Duarte, California • Irvine, California + 19 more

Search by objective public record fields.

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis

Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

SPARK-ALL: Calaspargase Pegol in Adults With ALL

A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)